Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Icon ( (ICLR) ) has issued an announcement.
On October 22, 2025, ICON plc reported its financial results for the third quarter of 2025, highlighting a revenue of $2,042.8 million, a 1.3% increase from the previous quarter. Despite a non-cash goodwill impairment charge of $165.3 million, the company achieved net business wins of $2,086 million, reflecting a net book to bill ratio of 1.02. The adjusted EBITDA for the quarter was $396.7 million, and the company repurchased $250 million worth of stock. ICON adjusted its full-year 2025 financial guidance, reflecting ongoing market challenges and increased pass-through revenues, with a revised revenue range of $8,050 – $8,100 million.
The most recent analyst rating on (ICLR) stock is a Buy with a $226.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score reflects solid financial health and positive earnings call insights, despite challenges in revenue growth and elevated cancellations. Technical indicators suggest moderate momentum, while valuation remains reasonable.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a leading clinical research organization headquartered in Dublin, Ireland. The company provides outsourced services to pharmaceutical, biotechnology, medical device, government, and public health organizations, advancing clinical research from molecule to medicine. As of September 30, 2025, ICON employed approximately 39,800 employees across 95 locations in 55 countries.
Average Trading Volume: 1,132,734
Technical Sentiment Signal: Hold
Current Market Cap: $14.66B
See more insights into ICLR stock on TipRanks’ Stock Analysis page.